 JERSEY CITY, N.J. GENEVA, Switzerland--BUSINESS WIRE-- Health--Organon NYSE: OGN, a global womens health company and ObsEva NASDAQ: OBSV SIX: OBSN, a biopharmaceutical company dedicated to improving womens reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant OBE022. Ebopiprant is an investigational, orally active, selective prostaglandin F2α PGF2α recep 